Liraglutide addition to SGLT2 inhibitors intensifies type 2 diabetes treatment: Study

Delhi: Liraglutide (1.8 mg) seems to be an effective way to intensify the treatment of type 2 diabetes irrespective of BMI, HbA1c, insulin resistance, diabetes duration, and SGLT2i use duration, according to results from a post-hoc analysis of the LIRA-ADD2SGLT2i trial. 

"For people with type 2 diabetes (T2D) and inadequate glycaemic control despite therapy with SGLT2is±metformin, liraglutide 1.8mg would provide an effective treatment intensification option, irrespective of HbA1c, BMI, diabetes duration, insulin resistance determined by HOMA-IR and SGLT2i use duration," the researchers reported in the journal Diabetes, Obesity and Metabolism.

The LIRA-ADD2SGLT2i trial has shown that in adults with T2D, liraglutide+sodium-glucose cotransporter-2 inhibitors (SGLT2is)±metformin significantly improved glycaemic control (not body weight) versus placebo. In this post-hoc analysis, Lawrence Blonde, Frank Riddick Diabetes Institute, New Orleans, LA, USA, and colleagues assessed whether baseline characteristics influenced these findings.

LIRA-ADD2SGLT2i is a placebo-controlled, double-blind, multinational trial, wherein participants were randomized in the ratio of 2:1 to receive liraglutide (≤1.8mg/day) or a placebo. Changes from baseline to week 26 in HbA1c, body weight and waist circumference (WC) stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analyzed. These five baseline characteristics were divided into tertiles, and the treatment effect was evaluated using the trial product estimand.